Publication:
Urinary proteomics revealed prostaglandin H<inf>2</inf>D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis

dc.contributor.authorPoorichaya Somparnen_US
dc.contributor.authorNattiya Hirankarnen_US
dc.contributor.authorAsada Leelahavanichkulen_US
dc.contributor.authorWeerapan Khovidhunkiten_US
dc.contributor.authorVisith Thongboonkerden_US
dc.contributor.authorYingyos Avihingsanonen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherFaculty of Medicine, Chulalongkorn Universityen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-11T04:36:13Z
dc.date.available2018-06-11T04:36:13Z
dc.date.issued2012-06-18en_US
dc.description.abstractAlthough renal histopathology is the gold standard for the diagnosis and prognosis of lupus nephritis (LN), the invasiveness of renal biopsy warrants the discovery of novel non-invasive diagnostic and prognostic biomarkers. In the present study, urine samples from 10 LN patients (5 active and 5 inactive) were analyzed by two-dimensional gel electrophoresis (2-DE) to screen for potential biomarkers of active LN. Quantitative analysis and statistics revealed 16 protein spots whose levels significantly differed between groups. These proteins were successfully identified by electrospray ionization quadrupole time-of-flight tandem mass spectrometry (ESI-Q-TOF MS/MS). Among these potential candidates, differential levels of urinary Zn-α2-glycoprotein (ZA2G) and prostaglandin H 2 D-isomerase (PGDS) were further validated by enzyme-linked immunosorbent assay (ELISA) in another independent group of 78 subjects, including 30 active LN, 26 inactive LN, 14 non-LN glomerular diseases, and 8 healthy normal individuals. Whereas ZA2G levels were elevated in urine of patients with active LN and non-LN glomerular diseases, PGDS was elevated only in the urine of the active LN group. Urinary PGDS, not ZA2G, may serve as a biomarker for active LN and upon validation in larger studies, may become the non-invasive test to evaluate the disease activity in future management of LN. © 2012 Elsevier B.V.en_US
dc.identifier.citationJournal of Proteomics. Vol.75, No.11 (2012), 3240-3247en_US
dc.identifier.doi10.1016/j.jprot.2012.03.034en_US
dc.identifier.issn18767737en_US
dc.identifier.issn18743919en_US
dc.identifier.other2-s2.0-84861717304en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/13698
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861717304&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleUrinary proteomics revealed prostaglandin H<inf>2</inf>D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861717304&origin=inwarden_US

Files

Collections